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Abstract
Introduction: Pneumocystis jirovecii is the causative organism of  Pneumocystis pneumonia (PCP) in humans, which is more 
common among immunocompromised patients. Classically patients present with fever, non-productive cough, and dyspnoea. In 
the HIV-infected individuals the symptoms may be subtle at first, but gradually progress over several weeks. In the HIV-uninfect-
ed patient, however, the duration of  symptoms is shorter and more severe, mainly due to the increased inflammatory response 
of  the HIV-uninfected patient.
Methods: This article  focuses on the diagnostic methods and then the management and prophylaxis principles of  PCP by re-
viewing the best current practices and guidelines in Africa.
Conclusion: This overview is presented by clinicians who have experience with PCP and is directed mainly at first-line health-
care providers.
Keywords: Pneumocystis jirovecii pneumonia, african generalist practitioner.
DOI: https://dx.doi.org/10.4314/ahs.v19i4.43
Cite as: Govender I, Maphasha OM, Rangiah S, Steyn C. An overview of  Pneumocystis jirovecii pneumonia for the African generalist 
practitioner. Afri Health Sci.2019;19(4):3200-3207. https://dx.doi.org/10.4314/ahs.v19i4.43
Corresponding author:
I Govender,
Department of  Family Medicine, 
Sefako Makgatho Health Sciences University
P.O. BOX 222, MEDUNSA 0204.
Email: indiran.govender@gmail.com
Background, history and epidemiology of  PCP
The causative organism of  Pneumocystis pneumonia (PCP) 
is the fungus Pneumocystis jirovecii.1 This organism was first 
classified as the protozoan Pneumocystis carinii, but the clas-
sification was changed in 1988.2 This is the only fungus 
in the Pneumocystis group that causes disease in humans.3 
Although the abbreviation PJP is sometimes used, PCP is 
still used for convenience to designate Pneumocystis pneu-
monia, and is the abbreviation for Pneumo Cystis (jirovecii) 
Pneumonia.4
This classification was based on the morphologic features 
and the resistance to classical antifungal agents. Both Car-
los Chagas and Antonio Carini found Pneumocystis in 
the lungs of  rats.2 Until the 1980s, the phylogenetic clas-
sification of  Pneumocystis as a protozoan was based on the 
histological characteristics of  its life cycle forms, trophic 
and cystic forms; inability to maintain in vitro cultures of  
the organism and successful response to treatment with 
anti-parasitic drugs, such as pentamidine or primaquine.5 
The affinity of  the species for the lung led to the identi-
fier Pneumocystis.2  The microbe was first described in hu-
mans by Otto Jirovec, after whom the disease was subse-
quently been named.6 The full and correct classification 
of  pneumocystis therefore took many years.2
PCP was first reported during World War II in crowd-
ed orphanages in Central and Eastern Europe among 
premature infants and malnourished children.3,7,8 In the 
1980s, the incidence of  PCP increased dramatically with 
the emergence of  HIV. However, the incidence of  the 
disease in the HIV-infected population has decreased sig-
nificantly due to the use of  anti-retroviral agents and PCP 
prophylaxis. An interesting finding in Sweden during the 
last stage of  a study that was done between 1991 and 
2001 showed that 75% of  PCP patients were HIV-un-
infected. This is the result of  other immunosuppressive 
conditions and treatments.3
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Pneumocystis organisms have been described in most mam-
mals. However, the organisms are host specific, and those 
that are infectious to humans will not infect any other 
mammalian species.2 Pneumocystis jirovecii is distributed 
worldwide and PCP has been described in all continents 
except Antarctica.8
PCP is one of  the most common potentially life-threat-
ening opportunistic diseases amongst patients with HIV/
AIDS, especially in those with CD4 cell counts of  less 
than 200 cells/mm3.2,9,10,11 It is classified as an AIDS-de-
fining illness and places the patient in the World Health 
Organization clinical stage4.1,13 Other factors associat-
ed with the risks for PCP infection in the HIV-infected 
population include oral thrush, recurrent bacterial pneu-
monia, previous PCP infection, unintentional weight 
loss and high viral load.13 Even though PCP remains an 
important cause of  HIV-associated pneumonia, the inci-
dence of  PCP is decreasing due to the use of  anti-retro-
viral therapy (ART) and initiation of  routine prophylaxis 
at low CD4 counts.10
 
In HIV-uninfected patients PCP is an emerging threat, 
and those who are at the highest risk for infection are 
transplant patients, those with cancer, chronic renal fail-
ure patients, patients with connective tissue diseases, and 
those who receive long courses of  glucocorticoids, che-
motherapy and other immunosuppressive agents.4.11,14,15 
Symptoms / presentation
The clinical presentation of  PCP is different in HIV-in-
fected and HIV-uninfected patients.14,16 These differ-
ences are mainly due to a severe inflammatory response 
in HIV-uninfected patients, which is not possible in 
the HIV-infected population.14,17 The severity of  PCP 
is therefore better determined by the inflammatory re-
sponse of  the host’s body than by the load of  organisms.
In HIV-infected patients, colonisation of  the lungs by P. 
jirovecii is very high, but the inflammatory response of  the 
host is ineffective.2,14 As a result, the clinical presentation 
of  PCP in this patient group is often insidious. The most 
common manifestations of  PCP are gradually progres-
sive dyspnoea, fever, non-productive cough, and chest 
discomfort that deteriorates within days to weeks before 
diagnosis. Patients typically present with these manifes-
tations after two weeks to two months of  the onset of  
symptoms.12,14 HIV-infected PCP patients have better 
oxygenation and survival rates, and this may be due to 
the smaller number of  inflammatory cells in this group.2 
Another factor that could contribute to better outcomes 
in this group is a higher index of  suspicion for PCP in 
HIV-infected patients by doctors, leading to more prompt 
diagnosis and initiation of  appropriate treatment.16
In HIV-uninfected patients there are smaller numbers 
of  the organism in the lungs, and this makes the detec-
tion and definitive diagnosis of  PCP more difficult.14 As 
a result of  this delay in diagnosis, the duration between 
hospital admission and commencement of  treatment for 
these patients is longer, thereby worsening the progno-
sis.16 The prognosis of  HIV-uninfected patients with 
PCP is worse than that of  HIV-infected patients, with 
mortality rates varying from 30% to 60%.14,16
Examination/physical signs
The primary manifestation of  Pneumocystis jirovecii in 
HIV-uninfected patients is pneumonia. In this patient 
group PCP initially manifests with fever, dyspnoea and 
dry cough, and then progress within one week to severe 
hypoxia, rapid respiratory deterioration and respiratory 
failure that requires mechanical ventilation. Respiratory 
insufficiency in these patients is severe, and the course of  
the pneumonia is fulminant.3,14,18 Should HIV-uninfect-
ed patients present with extra-pulmonary symptoms and 
shock, an alternative diagnosis should be considered.3
Even though the progression is slow, PCP can lead to 
respiratory failure, septic shock and death in HIV-infect-
ed patients.13 Survival rates in mechanically ventilated pa-
tients are low,17 and overall mortality rates are between 
10 and 20 percent.2,14 The prognosis of  HIV-infected pa-
tients with PCP has not improved much over the last 25 
years, despite major advances in the treatment of  HIV/
AIDS during this time.16
Lung auscultation in PCP patients is often unrevealing, 
but inspiratory crackles are the most common finding. 
However, patients may have signs of  respiratory com-
promise, which include cyanosis, tachycardia and tachy-
pnoea. PCP may present with unilateral or bilateral pneu-
mothorax, which is manifested by pleuritic chest pain and 
dyspnoea.1,2,18 
Special investigations
Radiological investigations
Chest radiography retains a key role in the clinical diag-
nosis of  pneumonia in the immunocompromised, even 
though the X-ray can be normal at initial presentation. It 
is the prime modality in the diagnosis of  pneumonia, and 
follow-up imaging is used to check for resolution.19
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The diagnosis of  PCP is suspected by the characteristic 
appearance of  the chest X-ray, which shows bilateral or 
diffuse ground-glass opacities. In some patients with PCP 
the ground-glass opacities are distributed in the sub-pleu-
ral lung parenchyma, whereas peripheral sparing of  
ground-glass opacities occurs in other patients.14 Exten-
sive areas of  symmetrical, bilateral ground-glass opacities 
are not seen in other types of  pneumonia.3
Appearances on radiographic imaging in HIV-infected 
and HIV-uninfected patients are similar,3,16 but may be 
varied, non-specific, and lag behind the symptoms. The 
classic appearance is of  bilateral symmetrical peri-hilar or 
diffuse interstitial ground-glass opacification, as seen in 
Figure 1, but may be reticular or finely granular in ap-
pearance. If  left untreated, this may progress to alveolar 
consolidation in three or four days. Infiltrates clear within 
two weeks, but in some patients infection will be followed 
by coarse reticular opacification and fibrosis.3,9,20
Although the findings are similar, ground-glass opacities 
may be more extensive and spread more rapidly, with-
 
 
Figure 1: Typical chest X-ray of Pneumocystis jirovecii pneumonia in an HIV-infected patient. The X-ray shows ground-glass 
opacities, diffuse patchy infiltrates and pneumatocoeles (arrows). Source: Zhao JB. Pneumonia in immunocompromised patients. 
Medscape. 2017. Available at: https://emedicine.medscape.com/article/807846-oerview21 
out peripheral sparing in HIV-uninfected patients. Lung 
consolidations may be more common in these patients 
due to pulmonary damage of  the inflammatory immune 
response.3,18 Although radiographic imaging is not a de-
finitive diagnostic tool, it is used clinically as PCR, serum 
β-D-glucan  and microscopy which are more definitive 
are expensive and not always available in the African clin-
ical context.4,14,16
In some instances PCP presents with normal chest ra-
diographs. Chest high-resolution computed tomography 
(HRCT) may be useful in these patients, demonstrating 
patchy areas of  ground-glass opacities,1,3,14 and with ex-
tensive ground-glass opacities being the main findings, as 
seen in Figure 2. A normal HRCT may in fact be used to 
exclude a diagnosis of  PCP.3,18
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Figure 2: Diffuse ground-glass opacities, thickening of interlobular septa and linear opacities (arrows) in a chest CT-scan of a 
HIV-infected patient with PCP. Source: Zhao JB. Pneumonia in immunocompromised patients. Medscape. 2017. Available 
at: https://emedicine.medscape.com/article/807846-overview21 
Microscopy and culture
Microscopic visualisation of  Pneumocystis jirovecii is the 
gold standard for the diagnosis of  PCP, because the or-
ganisms are very difficult to culture.18 Microscopy is 
done with organisms in sputum or broncho-alveolar la-
vage fluid.18 Sputum induction with hypertonic saline 
should be the initial procedure for microscopic diagnosis, 
especially in HIV-infected patients.2 However, HIV-un-
infected patients have a lower number of  the organisms, 
thereby making visualisation under microscopy more 
difficult, and rendering microscopic diagnosis with weak 
sensitivity for PCP.3,14 Giemsa staining is often used for 
microscopy, as seen in Figure 3, and the use of  an immu-
nofluorescence assay with anti-Pneumocystis antibodies can 
improve the microscopic visualisation of  cysts.3
 
 
Figure 3: A cytological preparation from a broncho-alveolar lavage shows the faint bluish, dot-like intra-cystic bodies (arrow) 
of Pneumocystis jirovecii with Giemsa stain at high magnification. Source: AIDS Pathology. The Internet Pathology Laboratory 
for Medical Education, The University of Utah. 2017. Available 
at: https://library.med.utah.edu/WebPath/TUTORIAL/AIDS/AIDS091.html22 
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Serum β-D-glucan
Serum β-D-glucan (BDG) is derived from the cell wall of  
several fungi, including Pneumocystis species., and although 
it is not specific for Pneumocystis, measurement of  serum 
BDG has been used for the diagnosis of  PCP.14 The se-
rum BDG test has a good negative predictive value, and 
the diagnostic performance of  the test seems to be better 
for PCP than for invasive fungal infections like aspergil-
losis or candidiasis.3 Serum BDG is assayed from a blood 
sample, requiring a red-top bottle. These red top collec-
tion glass tubes are vacusera serum clot activator tubes as 
per recognized international standards. BDG may how-
ever also be assayed on bronchial washings.4 BDG assays 
from broncho alveolar washings is often elevated in pa-
tients with PCP. The assay sensitivity appears to be high, 
and thus a diagnosis of  PCP is less likely in patients with 
low levels (e.g. <80 pg/ml using the Fungitell assay). The 
specificity for establishing a PCP diagnosis is low, since 
many other fungal diseases, as well as haemodialysis cellu-
lose membranes and some drugs can produce elevation.4
 
Polymerase chain reaction (PCR)
PCR is used increasingly for the diagnosis of  PCP due 
to its high sensitivity of  94% to 100%.14 This technique 
is often used in HIV-uninfected patients due to the high 
sensitivity.4,16 A negative PCR result allows for the with-
drawal of  PCP treatment, due to the high negative pre-
dictive value of  PCR for PCP.14,16
Bronchoscopy
If  the initial specimen of  induced sputum (induced spu-
tum by means of  nebulization or physiotherapy where 
the patient does not have a productive cough) is nega-
tive for PCP then bronchoscopy with broncho-alveolar 
lavage (BAL) should be performed.2 HIV-uninfected pa-
tients often have rapidly progressive respiratory insuffi-
ciency, thereby making diagnosis through bronchoscopy 
difficult.14 BAL fluid is however often required for micro-
scopic identification of  Pneumocystis jirovecii,18 as deep lung 
samples are required.4 BAL fluid has a 90% sensitivity for 
detecting PCP. Transbronchial biopsies are not common-
ly performed during bronchoscopy, because pneumotho-
races are more common in PCP and can be iatrogenically 
caused by this procedure.4
Management
Cotrimoxazole (trimethoprim/sulfamethoxazole) is the 
treatment of  choice for PCP of  any severity in HIV-in-
fected and HIV-uninfected patients. Treatment duration 
of  21 days is recommended for HIV-infected patients, 
and 14 days for HIV-uninfected immunocompromised 
patients.3,4,14,23 The longer duration of  treatment for 
HIV-positive patients is due to the higher number of  
organisms, a delayed clinical response to treatment, and 
a high probability of  relapse after a shorter treatment 
course.3,14 The treatment can be prolonged in HIV-un-
infected patients if  they show a poor clinical response 
to treatment, or if  they are severely immunocompro-
mised.11,14 Hospitalised patients should receive intrave-
nous therapy until they improve enough to reliably ab-
sorb oral medication, whilst those with mild disease can 
be treated with oral therapy. HIV-positive patients who 
are not on ART should be initiated on it.1,12,23 Failure to 
respond clinically to cotrimoxazole cannot be decided on 
until one week of  treatment has been completed.4
 
Cotrimoxazole is given in six-hourly doses for 21 days. 
The dosage is according to the patient’s weight; trimetho-
prim is given at 15-20 mg/kg, and sulfamethoxazole at 
75-100 mg/kg.3,23 Patients with a weight of  less than 
60 kg require three single-strength tablets, and patients 
with a weight of  more than 60 kg will require four sin-
gle-strength tablets. Treatment is given intravenously to 
patients who cannot swallow tablets for reasons such as 
excessive vomiting.12,23
Side-effects of  cotrimoxazole include nephrotoxicity, 
hepatotoxicity, bone marrow depression, and skin rash, 
and these could be an obstacle to adherence to treatment 
and completion of  the full treatment period.14,16 Patients 
who are allergic to cotrimoxazole should ideally be de-
sensitised, as this is the most effective form of  treatment. 
If  there is a history of  severe allergic reactions, e.g. Ste-
vens-Johnson syndrome, cotrimoxazole should be avoid-
ed, and desensitisation should not be attempted.11
If  a patient develops PCP despite being on prophylaxis, 
the treatment agent should be different from the prophy-
laxis agent if  the clinician believes that the patient had 
been compliant to the prophylaxis. The different options 
for treatment are summarised in Table 1.
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Clindamycin and primaquine
Pentamidine IV 
Oxygen by facemask or continuous positive airway pres-
sure (CPAP) should be given to hypoxic patients as nec-
essary.
Oral prednisone should be added for 21 days. The ad-
junctive steroid guideline is summarised in Table 1. The 
use of  corticosteroids in conjunction with anti-Pneumo-
cystis therapy decreases the incidence of  mortality and 
respiratory failure associated with severe PCP when ad-
ministered in the first 72 hours of  treatment, but should 
preferably be initiated with the anti-PCP treatment.4,12,18,23 
Corticosteroids blunt the inflammatory response in the 
patient’s lungs that was initiated by the degradation and 
clearance of  organisms, thereby attenuating lung injury.14
Patients on anti-PCP treatment should be monitored reg-
ularly, and oxygen saturation, pulse rate, blood pressure 
and temperature should be recorded. If  the condition of  
the patient deteriorates consider the development of  a 
pneumothorax, an additional infection, progression of  
PCP despite treatment, or treatment toxicity.4
 
Table 1: Treatment options for PCP. Source: Venkatesan P. Guidelines for the treatment of 
Pneumocystis jirovecii pneumonia (PCP) in adults. February 2017. Available 
from: www.nuh.nhs.uk/handlers.downloads.ashx?id=693474 
 
Severity of infection Drug options Adjunctive steroids 
First-line: For all degrees 
of severity 
Cotrimoxazole Prednisone: 
40 mg to be given 12-
hourly for five days. 
(An equivalent dose of 
an intravenous steroid 
can also be given 
initially.) 
40 mg to be given in the 
morning. Continue for 
the next five days. 
20 mg to be given in the 
morning, continue for 
the next eleven days. 
Steroids should be 
discontinued with or 
before acute anti-PCP 
treatment 
Second-
line: 
Mild PCP 
infection 
In descending order of 
preference: 
Dapsone and 
trimethoprim 
Atovaquone 
Moderate PCP 
infection 
In descending order of 
preference: 
Clindamycin and 
primaquine 
Dapsone and 
trimethoprim 
Severe PCP 
infection 
In descending order of 
preference: 
Clindamycin and 
primaquine 
Pentamidine IV 
 
Prophylaxis
Mortality of  PCP remains high despite intensive treat-
ment, and therefore prophylaxis is justified.14
Drug prophylaxis reduces the incidence of  PCP and 
lengthens the disease-free intervals between episodes. 
There is currently no PCP vaccine available.
Prophylaxis should be considered for:2,3,4,11,12,23
• All patients with a history of  Pneumocystis infec-
tion
• Severely immunocompromised patients
• All HIV-positive individuals with a CD4+ T-cell 
count below 200 cells/mm3
• Patients with malignancies
• Organ transplant recipients
• Patients with vasculitis and inflammatory diseases
• Patients with inflammatory bowel disease.
Prophylaxis should continue until immunity recovers 
sufficiently. Oral cotrimoxazole is the drug of  choice in 
HIV-infected and HIV-uninfected patients.12,14,23 The pro-
phylactic dosage is two single strength tablets daily.23 An 
alternative regimen is cotrimoxazole (80/400) one tablet 
daily, or two tablets three times per week.14
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Dapsone, pentamidine and atovaquone have also been 
used for prophylaxis as second-line in patients who can-
not tolerate cotrimoxazole.2,3,12 The recommended dose 
for dapsone is 2 mg/kg/day or 4 mg/kg/week. The max-
imum daily dose is 100 mg.12 When prescribing dapsone 
ensure that the patient does not have G6PD deficiency.12
Patients (particularly children) who start ART, attain low 
HIV viral loads and improved CD4 counts of  > 200 
cells/mm3 for three consecutive months, may discontin-
ue prophylactic therapy safely.12,23
 
Secondary prophylaxis
Patients who had PCP infection, who have been treated 
and are without symptoms, receive secondary prophylaxis 
or chronic maintenance therapy, which conforms to the 
same schedule as primary prophylaxis for each patient 
group.12,23 In descending order of  preference the options 
for secondary prophylaxis are cotrimoxazole, dapsone, 
atovaquone and aerosolised pentamidine.4
Secondary prophylaxis should be started concurrently 
with the end of  PCP treatment and continued for life, 
unless immune reconstitution occurs with ART.12,23
Secondary prophylaxis is discontinued when patients 
have immune reconstitution and a CD4 count increased 
from <200 cells/mm3 to >200 cells/mm3 for three con-
secutive months as a result of  ART. Prophylaxis should 
be continued for life in patients who develop PCP despite 
immune reconstitution.12,23
Special considerations during pregnancy
Pneumonia, including PCP, can cause acute lung injury 
in pregnant women. Although PCP can have an insidious 
onset, it can progress rapidly to acute respiratory failure 
and death for both the mother and the foetus.24
Prevention is the best form of  PCP management in 
pregnancy. Cotrimoxazole is the agent of  choice for 
chemoprophylaxis in pregnant patients with immuno-
suppression,12,24 is safe in pregnant and breastfeeding 
HIV-positive patients, and risks to the foetus are out-
weighed by the benefits.24
PCP in pregnancy has an aggressive course, and maternal 
and foetal outcomes are generally poor. PCP in pregnan-
cy should therefore be managed by a multidisciplinary 
team that involves a physician, obstetrician and pulmo-
nologist, and includes high doses of  cotrimoxazole and 
oxygen therapy.12,24
Acutely ill pregnant patients present an ethical dilemma 
to the treating team. Delivery of  the foetus may improve 
maternal ventilation and outcomes, but could compro-
mise the foetus, with complications like stillbirth and 
congenital transplacental infection.24  
 
Key messages
• PCP is a common cause of  morbidity and mortal-
ity in all immunocompromised patients.
• The classical presentation is initial fever, dys-
pnoea and cough.
• In HIV-uninfected patients the course of  the dis-
ease is fulminant and rapid with high mortality rates.
• In HIV-infected patients the course of  the dis-
ease is insidious, but can however lead to shock, respira-
tory failure and death.
• Radiographic imaging shows ground-glass opaci-
ties.
• The drug of  choice for treatment and chemopro-
phylaxis is cotrimoxazole.
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